The Wall Street Transcript
The Wall Street Transcript - In-Depth Interviews for Investors
Healthcare >> CEO Interviews >> July 30, 2014

Interview with the CEO and the Vice President, CFO: The Spectranetics Corporation (SPNC)

Drake, Scott
Scott Drake joined The Spectranetics Corporation as the Chief Executive Officer in August 2011. Prior to joining Spectranetics, Mr. Drake held the position of Senior Vice President, Operations of DaVita, Inc. (DVA), a leading U.S. provider of kidney care and dialysis. At DaVita, he had responsibility for business operations that generated approximately 20% of the company’s revenue, which exceeds $6 billion. Previously, Mr. Drake held several positions of increasing responsibility within various health care business units at Covidien plc over a period of 17 years. From 2006 to 2009, Mr. Drake was Global Business Unit President, Respiratory and Monitoring Solutions, a $1.5 billion business with 8,000 employees. Under his leadership, significant operational improvements were made, including revenue and profit growth, enhanced new product development pipeline, lifting of FDA consent decree, and lean six sigma operational excellence initiatives. Foundational to these accomplishments is an intense focus on new product development, organizational effectiveness and customer needs. From 2003 to 2006, he was President, Valleylab, a $375 million surgical device business, where organic revenue growth accelerated from 4% to 24% during his tenure. From 2001 to 2003, he was Vice President and General Manager, Critical Care, a $150 million business unit where revenue growth and operating profitability improved under his leadership. Prior to 2001, Mr. Drake held several positions in sales and marketing management within various medical device business units. Mr. Drake holds a B.S. in business administration from Miami University of Ohio. Profile
Childs, Guy A.
Guy A. Childs has served as Vice President, Chief Financial Officer of The Spectranetics Corporation since January 2003. In May 2002, Mr. Childs was appointed Acting Chief Financial Officer, a position he also held from May 1999 to December 1999. Since joining Spectranetics in September 1991, Mr. Childs has held various accounting and financial management positions, the most recent being Director of Finance, which he held from January 2000 to May 2002. Prior to joining Spectranetics, Mr. Childs worked for the public accounting firm of Deloitte & Touche, LLP, serving as a senior accountant on various audit engagements in the financial services, health care and manufacturing industries. Profile
TWST: Can you elaborate on what the company does and its core technologies?

Mr. Drake: Within our vascular intervention business, our products cross, prepare and treat blockages in the

Top Company Interviews

Microsoft Corporation
Intel Corporation
Pfizer, Inc.
General Electric Company
Walmart Inc.
International Business Machines Corporation
Citigroup Inc.
Exxon Mobil Corporation
Bank of America Corporation
Dell Inc.
Verizon Communications Inc.
Alphabet Inc

Register for a Free Account to gain greater access to The Wall Street Transcript right now

CEO INTERVIEWS
Interview with the CEO: BetterLife Pharma Inc. (OTCMKTS:BETRF)
Interview with the CEO: Cansortium Inc. (OTCMKTS:CNTMF)
Interview with the Co-CEO and the CAO: Planet 13 Holdings Inc. (OTCMKTS:PLNH)
SECTOR ROUNDTABLES
Natural Gas Weighs Heavy On E&P Near-Term Prospects
Roundtable Forum:optimism Despite Uncertainty In For-profit Education
Roundtable Forum:a Shift In Focus To Natural Gas From Oil
MONEY MANAGER INTERVIEWS
Profitability Strategy Pays Off for Bank IT Company Q2 Holdings
Three Mid-Cap Names Using Their Balance Sheets to Create Value
Look Beyond Traditional Emerging Markets for More Diversification, Less Risk
ANALYST INTERVIEWS
Five Companies Dominate in Psychedelics-Based Drug Development
Cidara’s Long-Acting Antiviral Drug Could Be a Game Changer
Spotting Potential in the High-Risk, High Reward Neuroscience Space
Since 1963
© The Wall Street Transcript 2016, 2024
Terms and Conditions
Privacy Policy